Nuo Therapeutics, Inc. (AURX) Return on equity 2017–2024
Nuo Therapeutics, Inc. (AURX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-452.3%FY2024 · since FY2017: -3102.0% → -452.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -452.3% | -147.1 pp |
| FY2023 | -305.2% | -160.5 pp |
| FY2022 | -144.7% | -133.3 pp |
| FY2021 | -11.4% | — |
| FY2017 | -3102.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice